Anti-LYZL2/ LYZD2 functional antibody

Anti-LYZL2/ LYZD2 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to LYZL2/LYZL2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0333-Ab-1/ GM-Tg-hg-SE0333-Ab-2Anti-Human LYZL2 monoclonal antibodyHuman
GM-Tg-rg-SE0333-Ab-1/ GM-Tg-rg-SE0333-Ab-2Anti-Rat LYZL2 monoclonal antibodyRat
GM-Tg-mg-SE0333-Ab-1/ GM-Tg-mg-SE0333-Ab-2Anti-Mouse LYZL2 monoclonal antibodyMouse
GM-Tg-cynog-SE0333-Ab-1/ GM-Tg-cynog-SE0333-Ab-2Anti-Cynomolgus/ Rhesus macaque LYZL2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0333-Ab-1/ GM-Tg-felg-SE0333-Ab-2Anti-Feline LYZL2 monoclonal antibodyFeline
GM-Tg-cang-SE0333-Ab-1/ GM-Tg-cang-SE0333-Ab-2Anti-Canine LYZL2 monoclonal antibodyCanine
GM-Tg-bovg-SE0333-Ab-1/ GM-Tg-bovg-SE0333-Ab-2Anti-Bovine LYZL2 monoclonal antibodyBovine
GM-Tg-equg-SE0333-Ab-1/ GM-Tg-equg-SE0333-Ab-2Anti-Equine LYZL2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0333-Ab-1/ GM-Tg-hg-SE0333-Ab-2; GM-Tg-rg-SE0333-Ab-1/ GM-Tg-rg-SE0333-Ab-2;
GM-Tg-mg-SE0333-Ab-1/ GM-Tg-mg-SE0333-Ab-2; GM-Tg-cynog-SE0333-Ab-1/ GM-Tg-cynog-SE0333-Ab-2;
GM-Tg-felg-SE0333-Ab-1/ GM-Tg-felg-SE0333-Ab-2; GM-Tg-cang-SE0333-Ab-1/ GM-Tg-cang-SE0333-Ab-2;
GM-Tg-bovg-SE0333-Ab-1/ GM-Tg-bovg-SE0333-Ab-2; GM-Tg-equg-SE0333-Ab-1/ GM-Tg-equg-SE0333-Ab-2
Products NameAnti-LYZL2 monoclonal antibody
Formatmab
Target NameLYZL2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LYZL2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0333-Ag-1Recombinant multi-species LYZL2/ LYZD2 protein


    Target information

    Target IDGM-SE0333
    Target NameLYZL2
    Gene ID119180
    Gene Symbol and SynonymsLYZD2,LYZL2
    Uniprot AccessionQ7Z4W2
    Uniprot Entry NameLYZL2_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000151033
    Target ClassificationN/A

    The target: LYZL2, gene name: LYZL2, also named as LYZD2. Lysozymes (see LYZ; MIM 153450), especially C-type lysozymes, are well-recognized bacteriolytic factors widely distributed in the animal kingdom and play a mainly protective role in host defense. LYZL2 is a member of a family of lysozyme-like genes (Zhang et al., 2005 [PubMed 16014814]).[supplied by OMIM, Apr 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.